Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00489658
Status:
TERMINATED
Last Update Posted:
2007-06-21
First Post:
2007-06-20
Brief Title:
Eflornithine Nifurtimox Late-Stage Human African Trypanosomiasis HATin West Nile Uganda
Sponsor:
Epicentre
Organization:
Epicentre
Study Overview
Official Title:
Efficacy and Safety of an Eflornithine Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis HAT in West Nile Uganda
Status:
TERMINATED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Because of unexpectedly reduced disease prevalence in the study area a pragmatic decision was taken to terminate recruitment in March 2003
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NECS
Brief Summary:
This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda in which the combination of eflornithine nifurtimox showed very promising efficacy and safety The studys purpose is to evaluate the efficacy and safety of this combination in a larger group of late-stage Human African trypanosomiasis sleeping sickness patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None